$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

$qlgn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000149315223015184 Filed on May 02, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022
Revenue	$1.627M	$1.390M	$4.984M
YoY Change	13.74%	-6.16%	-11.85%
Cost Of Revenue	$1.017M	$1.096M	$4.303M
YoY Change	1311.86%	-10.17%	-0.69%
Gross Profit	$610.5K	$293.7K	$680.8K
YoY Change	-55.06%	12.55%	-48.47%
Gross Profit Margin	37.52%	21.13%	13.66%
Selling, General & Admin	$2.835M	$2.925M	$11.79M
YoY Change	-4.41%	-10.9%	-3.92%
% of Gross Profit	464.39%	995.86%	1731.21%
Research & Development	$1.327M	$1.778M	$6.837M
YoY Change	-11.93%	9.38%	-41.65%
% of Gross Profit	217.29%	605.34%	1004.28%
Depreciation & Amortization	$19.00K	$52.91K	$152.6K
YoY Change	-20.83%	71.67%	34.76%
% of Gross Profit	3.11%	18.01%	22.41%
Operating Expenses	$5.178M	$4.703M	$27.16M
YoY Change	-7.07%	-4.18%	13.26%
Operating Profit	-$3.551M	-$4.409M	-$22.18M
YoY Change	-14.25%	-5.12%	-2.13%
Interest Expense	-$377.4K	-$42.41K	-$26.65K
YoY Change	-7930.29%	-827.44%	-162.43%
% of Operating Profit
Other Income/Expense, Net	$5.256K	-$111.8K	$881.7K
YoY Change	-72.69%	-126.24%	-81.35%
Pretax Income	-$3.546M	-$8.803M	-$21.30M
YoY Change	-13.98%	108.81%	19.05%
Income Tax	-$38.18K	-$271.3K	-$265.0K
% Of Pretax Income
Net Earnings	-$3.464M	-$6.372M	-$18.64M
YoY Change	-15.99%	51.04%	4.15%
Net Earnings / Revenue	-212.92%	-458.46%	-374.04%
Basic Earnings Per Share	-$0.69		-$4.85
Diluted Earnings Per Share	-$0.69	-$1.51	-$4.85
COMMON SHARES
Basic Shares Outstanding	5.052M shares	42.11M shares	3.840M shares
Diluted Shares Outstanding	5.052M shares		3.840M shares

Balance Sheet

Concept	2023 Q2	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.342M	$7.034M	$7.034M
YoY Change	-86.23%	-59.89%	-59.89%
Cash & Equivalents	$1.347M	$7.040M	$7.034M
Short-Term Investments
Other Short-Term Assets	$11.64K	$12.63K	$1.661M
YoY Change	-99.4%	-99.09%	20.39%
Inventory	$1.563M	$1.586M	$1.586M
Prepaid Expenses
Receivables	$679.4K	$538.6K	$538.6K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.863M	$10.82M	$10.82M
YoY Change	-64.52%	-47.97%	-47.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$498.6K	$345.1K	$1.768M
YoY Change	51.27%	68.98%	-4.44%
Goodwill	$625.6K	$625.6K
YoY Change	-87.22%
Intangibles	$5.833M	$5.846M
YoY Change	-0.43%	3314.75%
Long-Term Investments
YoY Change
Other Assets	$18.33K	$18.33K	$24.02K
YoY Change	0.01%	0.0%	31.04%
Total Long-Term Assets	$8.287M	$8.263M	$8.263M
YoY Change	-34.46%	305.18%	305.18%
TOTAL ASSETS
Total Short-Term Assets	$4.863M	$10.82M	$10.82M
Total Long-Term Assets	$8.287M	$8.263M	$8.263M
Total Assets	$13.15M	$19.08M	$19.08M
YoY Change	-50.09%	-16.43%	-16.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.756M	$857.3K	$857.3K
YoY Change	91.24%	-3.26%	-3.26%
Accrued Expenses	$1.981M	$1.512M	$1.928M
YoY Change	40.01%	-15.72%	3.43%
Deferred Revenue
YoY Change
Short-Term Debt	$965.2K	$950.7K	$950.7K
YoY Change	2.68%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.494M	$8.608M	$8.608M
YoY Change	50.44%	85.7%	85.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.197M	$1.351M	$1.351M
YoY Change	-20.0%	-17.4%	-17.4%
Total Long-Term Liabilities	$1.197M	$1.351M	$1.351M
YoY Change	-20.0%	-17.4%	-17.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.494M	$8.608M	$8.608M
Total Long-Term Liabilities	$1.197M	$1.351M	$1.351M
Total Liabilities	$9.842M	$10.32M	$11.85M
YoY Change	24.91%	64.52%	88.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.7M	-$103.4M
YoY Change	18.79%	22.01%
Common Stock	$42.95K	$42.11K
YoY Change	10.72%	19.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.034M	$7.236M	$7.236M
YoY Change
Total Liabilities & Shareholders Equity	$13.15M	$19.08M	$19.08M
YoY Change	-50.09%	-16.43%	-16.43%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$3.464M	-$6.372M	-$18.64M
YoY Change	-15.99%	51.04%	4.15%
Depreciation, Depletion And Amortization	$19.00K	$52.91K	$152.6K
YoY Change	-20.83%	71.67%	34.76%
Cash From Operating Activities	-$2.928M	-$2.238M	-$13.20M
YoY Change	-25.79%	-23.19%	-10.39%
INVESTING ACTIVITIES
Capital Expenditures	$48.41K	$244.4K	$164.7K
YoY Change	-449.53%	-1537.53%	-216.5%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$135.4K
YoY Change	-100.0%
Cash From Investing Activities	-$48.41K	-$244.4K	-$183.8K
YoY Change	-139.84%	1337.47%	30.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	2.903M	$2.911M
YoY Change		-64.37%	-65.49%
NET CHANGE
Cash From Operating Activities	-2.928M	-2.238M	-$13.20M
Cash From Investing Activities	-48.41K	-244.4K	-$183.8K
Cash From Financing Activities	0.000	2.903M	$2.911M
Net Change In Cash	-2.977M	421.2K	-$10.52M
YoY Change	-22.17%	-91.93%	63.41%
FREE CASH FLOW
Cash From Operating Activities	-$2.928M	-$2.238M	-$13.20M
Capital Expenditures	$48.41K	$244.4K	$164.7K
Free Cash Flow	-$2.977M	-$2.482M	-$13.36M
YoY Change	-24.3%	-14.3%	-8.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001460702
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	QLGN	Research And Development Grant Liability ResearchAndDevelopmentGrantLiability		usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2021Q4	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty		usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt		usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax		usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
CY2022	QLGN	Noncontrolling Interest Adjustments Relating To Stockbased Compensation And Other NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther		usd
CY2021	QLGN	Stock Issued Upon Netexercise Of Warrants StockIssuedUponNetexerciseOfWarrants		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	QLGN	Fair Value Of Warrants Issued For Professional Services FairValueOfWarrantsIssuedForProfessionalServices		usd
CY2021	QLGN	Fair Value Of Warrant Modification For Professional Services FairValueOfWarrantModificationForProfessionalServices		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	QLGN	Increase Decrease In Research And Development Grant Liability IncreaseDecreaseInResearchAndDevelopmentGrantLiability		usd
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities		usd
CY2021	QLGN	Purchases Of Equipment Held For Lease PurchasesOfEquipmentHeldForLease		usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2022	QLGN	Proceeds From Issuance Of Shares And Warrants Pursuant To Securities Purchase Agreements ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements		usd
CY2021	QLGN	Proceeds From Issuance Of Convertible Debt ProceedsFromIssuanceOfConvertibleDebt		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2021	QLGN	Fractional Share Payments Related To Reverse Stock Split FractionalSharePaymentsRelatedToReverseStockSplit		usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	QLGN	Issuance Of Common Stock For Conversion Of Preferred Stock Before Closing Of Reverse Recapitalization IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization		usd
CY2022	QLGN	Rightofuse Assets Obtained In Exchange For Operating Lease Liabilities RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities		usd
CY2022	QLGN	Shares Issued For Cashless Warrants Amount SharesIssuedForCashlessWarrantsAmount		usd
CY2022	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease		usd
CY2021	QLGN	Fair Value Of Warrant Modifications For Business Acquisition FairValueOfWarrantModificationsForBusinessAcquisition		usd
CY2021	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
CY2021	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		usd
CY2021	QLGN	Fair Value Of Warrants Repriced Due To Acquisition FairValueOfWarrantsRepricedDueToAcquisition		usd
CY2021	QLGN	Fair Value Of Qualigen Prefunded Warrant Issued In Exchange For Nanosynex Stock FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1		usd
CY2021Q4	QLGN	Fixed Asset Impairments FixedAssetImpairments		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	QLGN	Accrued Equipment Held For Lease AccruedEquipmentHeldForLease		usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2021Q4	QLGN	Accrued License Fees AccruedLicenseFees		usd
CY2022	QLGN	Dilutive Potential Shares Issuable From Stock Options And Warrants DilutivePotentialSharesIssuableFromStockOptionsAndWarrants		shares
CY2021	QLGN	Dilutive Potential Shares Issuable From Stock Options And Warrants DilutivePotentialSharesIssuableFromStockOptionsAndWarrants		shares
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		usd
CY2021Q4	QLGN	Deferred Tax Assets Research And Development Expenses DeferredTaxAssetsResearchAndDevelopmentExpenses		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37428
CY2022	dei	Entity Registrant Name EntityRegistrantName	Qualigen Therapeutics, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3474527
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2042 Corte Del Nogal
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92011
CY2022	dei	City Area Code CityAreaCode	(760)
CY2022	dei	Local Phone Number LocalPhoneNumber	918-9165
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	QLGN
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	21943148	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5052463	shares
CY2022	dei	Auditor Firm AuditorFirmId	23
CY2022	dei	Auditor Firm AuditorFirmId	23
CY2022	dei	Auditor Name AuditorName	BAKER TILLY US, LLP
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash Cash	7034434	usd
CY2021Q4	us-gaap	Cash Cash	17538272	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	538587	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	822351	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1586297	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1055878	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1661220	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1379896	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10820538	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	20796397	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	5690	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1422538	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1645568	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	345087	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	204217	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5845702	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	171190	usd
CY2022Q4	us-gaap	Goodwill Goodwill	625602	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18334	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18334	usd
CY2022Q4	us-gaap	Assets Assets	19083491	usd
CY2021Q4	us-gaap	Assets Assets	22835705	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	857311	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	886224	usd
CY2022Q4	QLGN	Accrued Vacation AccruedVacation	467948	usd
CY2021Q4	QLGN	Accrued Vacation AccruedVacation	282910	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1511856	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1510990	usd
CY2022Q4	QLGN	Research And Development Grant Liability ResearchAndDevelopmentGrantLiability	780682	usd
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	116161	usd
CY2021Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	135063	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240645	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134091	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	950722	usd
CY2022Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	788100	usd
CY2021Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	1686200	usd
CY2022Q4	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty	2834547	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	60197	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8608169	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4635479	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1301919	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1542564	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49056	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	92928	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	357757	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10316901	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6270971	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4210737	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4210737	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3529018	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3529018	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42110	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	35290	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	110528050	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101274073	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50721	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103385172	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84744629	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7235709	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16564734	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1530881	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16564734	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19083491	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22835705	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4983556	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5653725	usd
CY2022	QLGN	Cost Of Product Sales CostOfProductSales	4302755	usd
CY2021	QLGN	Cost Of Product Sales CostOfProductSales	4332485	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10835647	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11724964	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6837133	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11716718	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	950420	usd
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	542594	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	27164955	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	28316761	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-22181399	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-22663036	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	907203	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	4723187	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-26646	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	42693	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1125	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5446	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	881682	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4771326	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21299717	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17891710	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-265074	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5427	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-21034643	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-17897137	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2394100	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18640543	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-17897137	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.85
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.10
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3840340	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2933487	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-21034643	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-17897137	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	50721	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-20983922	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-17897137	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-2394100	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18589822	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17897137	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16564734	usd
CY2022	QLGN	Stock Issued Upon Cash Exercise Of Warrants StockIssuedUponCashExerciseOfWarrants	8031	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	5484044	usd
CY2022	QLGN	Common Stock And Prefunded Warrants Issued For Business Acquisition CommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition	7626142	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	50721	usd
CY2022	QLGN	Fair Value Of Warrant Modification For Professional Services FairValueOfWarrantModificationForProfessionalServices	67370	usd
CY2022	QLGN	Fair Value Of Warrant Modification For Business Acquisition FairValueOfWarrantModificationForBusinessAcquisition	696	usd
CY2022	QLGN	Stock Issued During Period Values Reverse Stock Splits StockIssuedDuringPeriodValuesReverseStockSplits	-505	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-21034643	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18294560	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18294560	usd
CY2021	QLGN	Stock Issued Upon Cash Exercise Of Warrants StockIssuedUponCashExerciseOfWarrants	2360189	usd
CY2021	QLGN	Issuance Of Common Stock For Conversion Of Preferred Stock IssuanceOfCommonStockForConversionOfPreferredStock	-1	usd
CY2021	QLGN	Fair Value Of Warrants Issued For Professional Services FairValueOfWarrantsIssuedForProfessionalServices	298651	usd
CY2021	QLGN	Shares Issued Pursuant To Securities Purchase Agreements SharesIssuedPursuantToSecuritiesPurchaseAgreements	8820000	usd
CY2021	QLGN	Commission And Offering Costs Of Securities Purchase Agreements CommissionAndOfferingCostsOfSecuritiesPurchaseAgreements	-2960465	usd
CY2021	QLGN	Fair Value Of Warrant Modifications Pursuant To Securities Purchase Agreements FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements	2253536	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	101750	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5293651	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-17897137	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16564734	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16564734	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-21034643	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-17897137	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	152573	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	113218	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	223030	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	225059	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-59982	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-247845	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	18943	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	-108138	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	101750	usd
CY2021	QLGN	Fair Value Of Warrants Issued For Professional Services FairValueOfWarrantsIssuedForProfessionalServices	298651	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5484044	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5293651	usd
CY2022	QLGN	Fair Value Of Warrant Modification For Professional Services FairValueOfWarrantModificationForProfessionalServices	67370	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-906345	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4723187	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-417708	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-41250	usd
CY2022	QLGN	Increase Decrease In Inventory And Equipment Held For Leases IncreaseDecreaseInInventoryAndEquipmentHeldForLeases	637410	usd
CY2021	QLGN	Increase Decrease In Inventory And Equipment Held For Leases IncreaseDecreaseInInventoryAndEquipmentHeldForLeases	-111422	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	99251	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1298998	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-33397	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	385455	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-76266	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	75336	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	120942	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1047163	usd
CY2022	QLGN	Increase Decrease In Research And Development Grant Liability IncreaseDecreaseInResearchAndDevelopmentGrantLiability	-534426	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-134091	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-254740	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-62775	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-416312	usd
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-271622	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13247540	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14730742	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	164684	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	134471	usd
CY2022	QLGN	Purchases Of Equipment Held For Lease PurchasesOfEquipmentHeldForLease	154433	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6893	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	135354	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-183763	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-141364	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7173	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	459476	usd
CY2021	QLGN	Proceeds From Issuance Of Shares And Warrants Pursuant To Securities Purchase Agreements ProceedsFromIssuanceOfSharesAndWarrantsPursuantToSecuritiesPurchaseAgreements	8820000	usd
CY2022	QLGN	Proceeds From Issuance Of Convertible Debt ProceedsFromIssuanceOfConvertibleDebt	2903847	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	706929	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	138739	usd
CY2022	QLGN	Fractional Share Payments Related To Reverse Stock Split FractionalSharePaymentsRelatedToReverseStockSplit	505	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2910515	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8433808	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10520787	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6438298	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22639	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17538272	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23976570	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7040123	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17538272	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1233	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5571	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5133	usd
CY2021	QLGN	Issuance Of Common Stock For Conversion Of Preferred Stock Before Closing Of Reverse Recapitalization IssuanceOfCommonStockForConversionOfPreferredStockBeforeClosingOfReverseRecapitalization	243	usd
CY2021	QLGN	Rightofuse Assets Obtained In Exchange For Operating Lease Liabilities RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities	1439830	usd
CY2021	QLGN	Shares Issued For Cashless Warrants Amount SharesIssuedForCashlessWarrantsAmount	764657	usd
CY2021	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease	1304	usd
CY2022	QLGN	Fair Value Of Warrant Modifications Pursuant To Securities Purchase Agreements FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements	9439	usd
CY2021	QLGN	Fair Value Of Warrant Modifications Pursuant To Securities Purchase Agreements FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreements	2253536	usd
CY2022	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise	858	usd
CY2021	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise	1900713	usd
CY2022	QLGN	Fair Value Of Warrant Modifications For Business Acquisition FairValueOfWarrantModificationsForBusinessAcquisition	33543	usd
CY2022	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	5896278	usd
CY2022	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	2321845	usd
CY2022	QLGN	Fair Value Of Warrants Repriced Due To Acquisition FairValueOfWarrantsRepricedDueToAcquisition	696	usd
CY2022	QLGN	Fair Value Of Qualigen Prefunded Warrant Issued In Exchange For Nanosynex Stock FairValueOfQualigenPrefundedWarrantIssuedInExchangeForNanosynexStock	1804102	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1904989	usd
CY2022	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	135354	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	These warrants were subsequently exercised on September 13, 2022
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zp75wf8bIeGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zng6SGdCYpk5">Accounting Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and warranty costs. Actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Reverse Stock Split On November 23, 2022, the Company effected a 1-for-10, as determined by the Company’s board of directors, reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced the Company’s shares of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.
CY2021	QLGN	Allowances For Sales Return AllowancesForSalesReturn	150000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4239000	usd
CY2022Q2	QLGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Research And Development Expense BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentExpense	5700000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	726449	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	958448	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	187862	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	136097	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	538587	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	822351	usd
CY2022	QLGN	Allowances For Sales Return AllowancesForSalesReturn	96000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	50000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2022	us-gaap	Product Warranty Expense ProductWarrantyExpense	69000	usd
CY2021	us-gaap	Product Warranty Expense ProductWarrantyExpense	57000	usd
CY2022Q4	us-gaap	Cash Cash	7000000.0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103400000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13200000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14700000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8800000	usd
CY2022Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3000000.0	usd
CY2022	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	the Company with a face value equal to the amount paid by the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the principal balance from time to time outstanding under the particular promissory note, convertible at the option of the Company into additional shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex issue additional shares. The principal of the convertible notes are due and payable upon the sooner to occur of: i) five years from the date of issuance of the particular promissory note; ii) the acquisition by any person or entity of all or substantially all of the share capital of NanoSynex, through share purchase, issuance or shares or merger of NanoSynex, or the purchase of all or substantially all of the assets of NanoSynex; or iii) the initial public offering of NanoSynex.
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	7048	shares
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	345087	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	4588	usd
CY2022Q2	QLGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses And Other Payables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherPayables	-291093	usd
CY2022Q2	QLGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Research And Development Grant Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedResearchAndDevelopmentGrantLiability	-1362264	usd
CY2022Q2	QLGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Short Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt	-941898	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	629379	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	-3882225	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	1215169	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4789602	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	3574433	usd
CY2022	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	117775	usd
CY2022	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	106621	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	4983556	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	5653725	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-19538959	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-17897137	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	949796	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	823315	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	200318	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	188135	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	436183	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	44428	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1586297	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1055878	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	204217	usd
CY2022	us-gaap	Depreciation Depreciation	92000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1377323	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1197726	usd
CY2022Q4	QLGN	Prepaid Manufacturing Expenses PrepaidManufacturingExpenses	43820	usd
CY2021Q4	QLGN	Prepaid Manufacturing Expenses PrepaidManufacturingExpenses	67410	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	227451	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	111183	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12626	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3577	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1661220	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1379896	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5043533	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4745455	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4623446	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4541238	usd
CY2022Q4	QLGN	Fixed Asset Impairments FixedAssetImpairments	-75000	usd
CY2021	us-gaap	Depreciation Depreciation	73000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	625602	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	752237	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	726749	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	145702	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	171190	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5845702	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	171190	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	18000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	15000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	14000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	14000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	14000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	65000	usd
CY2022Q4	QLGN	Accrued Compensation AccruedCompensation	70000	usd
CY2021Q4	QLGN	Accrued Compensation AccruedCompensation	17500	usd
CY2022Q4	QLGN	Accrued Equipment Held For Lease AccruedEquipmentHeldForLease	154433	usd
CY2022Q4	QLGN	Accrued Franchise Sales And Use Taxes AccruedFranchiseSalesAndUseTaxes	27531	usd
CY2021Q4	QLGN	Accrued Franchise Sales And Use Taxes AccruedFranchiseSalesAndUseTaxes	14090	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4663	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3620	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2829	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	209303	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	682036	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	238211	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	225308	usd
CY2022Q4	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	322987	usd
CY2021Q4	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	232712	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13158	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	10152	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	137568	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	60281	usd
CY2022Q4	QLGN	Accrued License Fees AccruedLicenseFees	150130	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	181043	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	265292	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1511856	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1510990	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3840340	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2933487	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3840340	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2933487	shares
CY2021Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	1686200	usd
CY2022	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise	858	usd
CY2022	QLGN	Fair Value Of Warrant Liabilities Issuance Of Alpha Warrants FairValueOfWarrantLiabilitiesIssuanceOfAlphaWarrants	-2834547	usd
CY2022	QLGN	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-897242	usd
CY2022Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	3622647	usd
CY2020Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	8310100	usd
CY2021	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise	1900713	usd
CY2021	QLGN	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-4723187	usd
CY2021Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	1686200	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18640543	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-17897137	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	462000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5183629	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1466326	shares
CY2021Q4	us-gaap	Area Of Land AreaOfLand	22624	sqft
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	November 1, 2022 to November 30, 2027
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	us-gaap	Payments For Rent PaymentsForRent	1950710	usd
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	QLGN	Tenant Improvement Allowance TenantImprovementAllowance	339360	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	368341	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	379392	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	390773	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	402497	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	379164	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1920168	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	377604	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1542564	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	342000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depletion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion	-0.0119	pure
CY2022Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	96558	usd
CY2022	QLGN	License Cost LicenseCost	40000	usd
CY2021	QLGN	License Cost LicenseCost	60000	usd
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5183629	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5183629	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5183629	shares
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3300000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y11M4D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.03	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.02	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0158	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0377	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0084	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0151	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M26D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M7D
CY2022	QLGN	Effective Income Tax Rate Reconciliation Non Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration	-0.1296	pure
CY2021	QLGN	Effective Income Tax Rate Reconciliation Non Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration	-0.0271	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depletion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion	-0.0136	pure
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5484044	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5293651	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	60000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.20
CY2021	QLGN	Fair Value Of Issuance Cost FairValueOfIssuanceCost	300000	usd
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	219101	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	40.70
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15954750	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17891710	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5344967	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21299717	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17891710	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0546	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0663	pure
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3069000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0242	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0086	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.0450	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Foreign EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign	0.0050	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Foreign EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign	0.0000	pure
CY2022	QLGN	Effective Income Tax Rate Reconciliation Fair Value Of Warrant EffectiveIncomeTaxRateReconciliationFairValueOfWarrant	0.0089	pure
CY2021	QLGN	Effective Income Tax Rate Reconciliation Fair Value Of Warrant EffectiveIncomeTaxRateReconciliationFairValueOfWarrant	0.0554	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.0147	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0272	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1168	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2744	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0124	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0003	pure
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-236000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1268000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2252000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3641000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-272000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2760000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4909000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-2488000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-4909000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-265000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33540000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33362000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7857000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6185000	usd
CY2022Q4	QLGN	Defferd Tax Assets Accrued Expenses DefferdTaxAssetsAccruedExpenses	1020000	usd
CY2021Q4	QLGN	Defferd Tax Assets Accrued Expenses DefferdTaxAssetsAccruedExpenses	757000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	262000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2747000	usd
CY2022Q4	QLGN	Deferred Tax Assets Research And Development Expenses DeferredTaxAssetsResearchAndDevelopmentExpenses	1196000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	280000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	282000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	46962000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	43595000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1324000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	34000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	382000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	436000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1706000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	470000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45256000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43125000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45614000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43125000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	358000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-272000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	119254000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	110227000	usd
CY2022	us-gaap	Tax Credit Carryforward Limitations On Use TaxCreditCarryforwardLimitationsOnUse	The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite life for state tax purposes
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd

Files In Submission

Name	View Source	Status
qlgn-20221231_cal.xml	Edgar Link	unprocessable
0001493152-23-015184-index-headers.html	Edgar Link	pending
0001493152-23-015184-index.html	Edgar Link	pending
0001493152-23-015184.txt	Edgar Link	pending
0001493152-23-015184-xbrl.zip	Edgar Link	pending
ex10-10.htm	Edgar Link	pending
ex10-10_001.jpg	Edgar Link	pending
ex10-10_002.jpg	Edgar Link	pending
ex10-11.htm	Edgar Link	pending
ex10-11_001.jpg	Edgar Link	pending
ex10-11_002.jpg	Edgar Link	pending
ex10-21.htm	Edgar Link	pending
ex10-21_001.jpg	Edgar Link	pending
ex10-31.htm	Edgar Link	pending
ex10-32.htm	Edgar Link	pending
ex10-33.htm	Edgar Link	pending
ex10-8.htm	Edgar Link	pending
ex10-8_001.jpg	Edgar Link	pending
ex10-8_002.jpg	Edgar Link	pending
ex10-9.htm	Edgar Link	pending
ex10-9_001.jpg	Edgar Link	pending
ex10-9_002.jpg	Edgar Link	pending
ex10-9_003.jpg	Edgar Link	pending
ex10-9_004.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qlgn-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qlgn-20221231_def.xml	Edgar Link	unprocessable
qlgn-20221231_pre.xml	Edgar Link	unprocessable
qlgn-20221231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

2023 Q2 Form 10-K Financial Statement

#000149315223015184 Filed on May 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN Qualigen Therapeutics, Inc. Stock $qlgn

2023 Q2 Form 10-K Financial Statement

#000149315223015184 Filed on May 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn